Short report

Passive transfer studies in demyelinating neuropathy with IgM monoclonal antibodies to myelin-associated glycoprotein

ANDREAS J STECK,* NORMAN MURRAY,* JEAN-CLAUDE JUSTAFRE,* CLAUS MEIER,† KLAUS V TOYKA,‡ KURT HEININGER,‡ GUIDO STOLL‡

From the Departments of Neurology, Universities of Lausanne* and Bern,† Switzerland and the Department of Neurology, University of Düsseldorf,‡ Federal Republic of Germany

SUMMARY Serum or IgM fraction from two patients with a demyelinating neuropathy and IgM monoclonal antibodies to myelin-associated glycoprotein were injected in three different animal species. There were no clinical, electrophysiological or morphological signs of demyelination in either chronic or acute passive transfer experiments. These results suggest that the pathogenesis of this human demyelinating neuropathy may be more complex than has been assumed.

Several recent reports have described a demyelinating neuropathy in the setting of an IgM gammopathy with antibody activity to a myelin antigen referred to as myelin-associated glycoprotein.1-3 This well-established clinical association, together with the presence of wide separation of the myelin lamellae that has been shown systematically in these cases,2,4 suggests that the demyelination may reflect antibody-mediated damage to the peripheral nerve. To test this assumption we have performed passive transfer experiments. We wish to report our inability to induce a neuropathy in both chronic and acute passive transfer experiments.

Patients and methods

Serum was obtained from two patients (PB and AK) with a demyelinating neuropathy associated with a monoclonal IgM gammopathy and from one control with IgM gammapathy without neuropathy. Clinical and pathological data have been described elsewhere.2,5 The monoclonal immunoglobulins from the two patients with neuropathy had proven specificity for myelin-associated glycoprotein.1 For chronic experiments, the human IgM was prepared from the sera by euoglobulin precipitation followed by gel filtration on sepharose 4B (Pharmacia) in 0.1 M Tris-HCl pH 8.0, 0.15 M NaCl. Before injection the material was sterilised by membrane filtration.

Address for reprint requests: Dr Steck, Department of Neurology, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.

Received 28 December 1984. Accepted 9 February 1985

Chronic experiments: (1) Two adult guinea pigs received an initial dose of human IgM (40 mg/kg), the test animal received IgM from patient PB while the other animal served as control. One day later the animals received an immunosuppressive dose of cyclophosphamide (300 mg/kg). Thereafter the animals received intraperitoneal injections of human IgM (40 mg/kg) every third day during 20 weeks. Blood samples were obtained by cardiac puncture after 6 and 20 weeks of treatment to determine the levels of circulating human IgM by rate immunonephelometry (Beckman) and to test for anti-myelin-associated glycoprotein activity.2 Motor nerve conduction velocity was measured at both sciatic nerves with the anaesthetised animals.7 Measurements were made every 2 weeks.

(2) One adult marmoset (Callithrix jacchus) received doses of human IgM (patient PB), ranging from 300–800 mg/kg, every other day during 13 weeks. The injections were given into the dorsal musculature and in part subcutaneously. At the end of the experiment blood was taken to determine the level of circulating human IgM. Motor nerve conduction velocity was measured as described7 every week.

(3) In an effort to improve the accessibility of the target antigen to the injected IgM, newborn rabbits were used. Four, 2-day-old rabbits housed with the mother received intraperitoneal injections of human IgM (50 mg/kg) every other day for 4 weeks. The two test animals received IgM from patient AK while the other two served as controls. At the end of the experiment blood was taken from the animals to determine the levels of circulating human IgM and to test for anti-myelin-associated glycoprotein activity.

At the end of all of the above experiments animals were killed and the sciatic nerves were rapidly dissected and...
prepared for immunocytochemistry using the PAP method and for light and electron microscopy.  

**Acute experiment:** Six adult rabbits were anaesthetised and, after lumbar laminectomy, they received a single intrathecal injection of human serum (0.3 to 0.5 ml). Two test animals were injected with serum from patient PB, two with serum from patient AK and two with control serum. Animals were killed after 3 or 10 days. The lumbo-sacral spinal roots and the cauda equina were removed and prepared for immunocytochemistry using the PAP method and for light and electron microscopy.

**Results**

All of the animals injected with human IgM on a chronic basis were found to have detectable quantities of human IgM in the circulation, levels ranged from 1 g/l in the experiment with guinea pigs to 15 g/l, or more, in the experiments with rabbits and monkeys. Immunoblotting studies confirmed that the sera of the test animals contained human antibody to myelin-associated glycoprotein while the sera of the control animals did not.

None of the animals involved in acute or chronic passive transfer experiments showed neurological deficit during the observation period. Electrophysiological measurements made during the experiments (with guinea pigs and monkey) failed to show any slowing of motor nerve conduction velocity. Light and electron microscopy revealed no evidence of nerve damage suggestive of an autoimmune polyneuropathy. Teased fibre preparations displayed no evidence of paranodal or segmental demyelination. Direct immunocytochemical studies performed on paraffin sections of sciatic nerve (chronic experiments) or lumbo-sacral roots (acute experiment) failed to reveal deposits of human IgM on nerve myelin. In the monkey but not the other species, these studies showed the IgM to be located at the perineurium (fig a). In contrast, indirect immunocytochemical studies confirmed that the human anti-myelin-associated glycoprotein IgM bound specifically to nerve myelin in the species used for these experiments (fig b).

**Discussion**

Passive transfer of serum from patients with autoimmune diseases such as myasthenia gravis" or Lambert-Eaton syndrome has been used extensively to demonstrate the pathogenic role of circulating immunoglobulins. Although a pathogenic role of monoclonal anti-myelin-associated glycoprotein IgM antibodies found in patients with a demyelinating neuropathy has been postulated, this has not yet been positively demonstrated, except for a preliminary report where intraneural injections were used, which is technically questionable. We chose therefore the passive transfer of intraperitoneally or intramuscularly applied immunoglobulins, an approach which has been shown to be effective in producing morphological and electrophysiological changes in peripheral nerves of animals receiving monoclonal IgM from patients with myelomatous polyneuropathy. For these transfer experiments we have used convenient laboratory species in which myelin-associated glycoprotein has been shown to crossreact with the human monoclonal IgM. Our findings highlight the problem of accessibility of the relevant target antigen, myelin-associated glycoprotein, to the large IgM molecules in the circulation. Thus, animals injected with human anti-myelin-associated glycoprotein IgM were found to have detectable quantities of human IgM in the circula.
tion and to have significant circulating anti-myelin-associated glycoprotein activity. In spite of this, however, no evidence of IgM deposits in nerve myelin could be demonstrated. This finding is in sharp contrast to the situation in patients with antibodies to myelin-associated glycoprotein in whom IgM deposits on the myelin sheaths have been described.\textsuperscript{13} In this context it is perhaps relevant that patients with non-malignant, as well as with malignant (Waldenström's macroglobulinaemia) gangliosopathy show changes in endoneurial microvasculature,\textsuperscript{14} and such changes have been observed in patient AK.\textsuperscript{2} It is conceivable that these changes may increase vascular permeability and improve antibody access to the nerve. In the experiments described here we have attempted to improve the access of the IgM to its target antigen. One approach involved chronic administration of IgM to newborn rabbits, during a period of one month. In these young animals the blood-nerve barrier may not be fully developed and the anti-myelin-associated glycoprotein IgM will be in the circulation during the period of rapid myelination. Our results show, however, that even under these circumstances the IgM does not penetrate the nerve. Another approach involved intrathecal administration of the serum. With this approach, however, only a single dose was given and again we found no evidence of IgM binding to myelin or to any other structure in the lumbo-sacral roots. The absence of an acute effect of anti-myelin-associated glycoprotein IgM may not be wholly unexpected in view of the very slowly progressive character of the neuropathy seen in the patients.

Recent evidence suggests that the human monoclonal IgM antibodies which recognise myelin-associated glycoprotein react with a carbohydrate epitope and it has been reported that this epitope is shared by a ganglioside of peripheral nerve.\textsuperscript{15} This ganglioside could conceivably be an important target antigen involved in the demyelination but further studies concerning its chemical identity, localisation in nerve and species restriction are required to clarify this. In conclusion the pathogenic potential of human anti-myelin-associated glycoprotein IgM remains to be demonstrated but our findings suggest that the pathogenesis of this human neuropathy is more complex than has been assumed.

This study was supported by grants from the Swiss Multiple Sclerosis Society, the Swiss National Science Foundation, the Deutsche Forschungsgemeinschaft and the Minister for Science and Research, NRW.

References

15. Ilyas AA, Quarles RH, MacIntosh TD, Dobersen MT, Trapp BD, Dalakas MC, Brady RO. IgM in a human neuropathy related to paraproteinaemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc Natl Acad Sci USA 1984;81:1225–9.